Compare ARQT & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | ATRC |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 1.6B |
| IPO Year | 2020 | 2005 |
| Metric | ARQT | ATRC |
|---|---|---|
| Price | $28.85 | $39.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $24.83 | ★ $52.22 |
| AVG Volume (30 Days) | ★ 1.8M | 450.9K |
| Earning Date | 10-28-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $317,929,000.00 | ★ $518,304,999.00 |
| Revenue This Year | $85.51 | $16.90 |
| Revenue Next Year | $30.74 | $12.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.21 | 15.80 |
| 52 Week Low | $11.13 | $28.29 |
| 52 Week High | $31.77 | $43.11 |
| Indicator | ARQT | ATRC |
|---|---|---|
| Relative Strength Index (RSI) | 52.58 | 50.78 |
| Support Level | $27.71 | $40.11 |
| Resistance Level | $30.26 | $41.33 |
| Average True Range (ATR) | 1.06 | 1.10 |
| MACD | -0.24 | -0.37 |
| Stochastic Oscillator | 49.91 | 16.07 |
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.